Pharma Guidelines, ending 10 October 2011
This article was originally published in SRA
Recently updated and newly issued documents
You may also be interested in...
The 2021 work plan of PIC/S, the international group of pharmaceutical inspectorates, includes renewed efforts to carry out projects that could not be completed due to the coronavirus pandemic.
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.